Evidence map›Paper›PMID 36899015›Full record

ArticleScientific reports2023

Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study.

Marta Truffi, Maria Garofalo, Alessandra Ricciardi, Matteo Cotta Ramusino, Giulia Perini, Silvia Scaranzin, Matteo Gastaldi, Sara Albasini, Alfredo Costa, Viola Chiavetta and 3 more

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Marta Truffi *Istituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy.
Maria Garofalo *Molecular Biology and Transcriptomics Unit, IRCCS Mondino Foundation, 27100, Pavia, Italy.
Alessandra RicciardiIstituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy.
Matteo Cotta RamusinoUnit of Behavioral Neurology and Center for Cognitive Disorders and Dementia (CDCD), IRCCS Mondino Foundation, 27100, Pavia, Italy.
Giulia PeriniUnit of Behavioral Neurology and Center for Cognitive Disorders and Dementia (CDCD), IRCCS Mondino Foundation, 27100, Pavia, Italy.
Silvia ScaranzinNeuroimmunology Laboratory, IRCCS Mondino Foundation, 27100, Pavia, Italy.
Matteo GastaldiNeuroimmunology Laboratory, IRCCS Mondino Foundation, 27100, Pavia, Italy.
Sara AlbasiniIstituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy.
Alfredo CostaUnit of Behavioral Neurology and Center for Cognitive Disorders and Dementia (CDCD), IRCCS Mondino Foundation, 27100, Pavia, Italy.
Viola ChiavettaIstituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy.
Fabio CorsiIstituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy.
Carlo Morasso *Istituti Clinici Scientifici Maugeri IRCCS, 27100, Pavia, Italy. carlo.morasso@icsmaugeri.it.
Stella Gagliardi *Molecular Biology and Transcriptomics Unit, IRCCS Mondino Foundation, 27100, Pavia, Italy. stella.gagliardi@mondino.it.
Istituti Clinici Scientifici Maugeri · ITUrology Foundation · GBFondazione Istituto Neurologico Nazionale Casimiro Mondino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofilament light chains (NfL) are neuron-specific cytoskeletal proteins whose plasmatic concentrations have been explored as a clinically useful marker in several types of dementia. Plasma concentrations of NfL are extremely low, and just two assays are commercially available for their study: one based on the SiMoA technology and one based on Ella. We thus studied plasma levels of NfL with both platforms to check the correlation between them and to assess their potential in the diagnosis of neurodegeneration. Plasma NfL levels were measured on 50 subjects: 18 healthy controls, 20 Alzheimer's disease, and 12 frontotemporal dementia patients. Ella returned plasmatic NfL levels significantly higher than SiMoA, however the results were strongly correlated (r = 0.94), and a proportional coefficient of 0.58 between the two assays was calculated. Both assays detected higher plasma NfL levels in patients with dementia than in the control group (p < 0.0001) and allowed their discrimination with excellent diagnostic performance (AUC > 0.95). No difference was found between Alzheimer's and Frontotemporal dementia either using SiMoA or Ella. In conclusion, both the analytical platforms resulted effective in analysing plasma levels of NfL. However, the correct interpretation of results requires the precise knowledge of the assay used.

Indexed as

Alzheimer DiseaseFrontotemporal DementiaBiomarkersCytoskeletal ProteinsHumansIntermediate FilamentsNeurofilament ProteinsBiomarkersCytoskeletal ProteinsNeurofilament Proteins

Identifiers

PMID36899015
PMCPMC10006166
OpenAlexW4323833911

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read22
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.